Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liafensine - Denovo Biopharma

Next Previous
Drug Profile

Liafensine - Denovo Biopharma

Alternative Names: BMS-820836; DB 104

Latest Information Update: 27 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AMRI
  • Developer Bristol-Myers Squibb; Denovo Biopharma
  • Class Antidepressants; Isoquinolines; Naphthalenes; Pyridazines; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Depressive disorders
  • Preclinical Major depressive disorder

Most Recent Events

  • 23 Jun 2025 Liafensine licensed to Chuang Yi Global Asset Management in Taiwan
  • 09 Oct 2024 Liafensine - Denovo Biopharma receives Fast Track designation for Depressive disorders [PO] (Treatment-resistant) in USA
  • 03 Apr 2024 Liafensine is available for market licensing

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top